Quantitative Risk/Benefit Assessment: Where Are We?
暂无分享,去创建一个
[1] Jonathan D. Norton,et al. A Longitudinal Model and Graphic for Beneft-risk Analysis, With Case Study , 2011 .
[2] B S Levitan,et al. Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit–Risk Balance of Medicines , 2011, Clinical pharmacology and therapeutics.
[3] B S Levitan,et al. Application of the BRAT Framework to Case Studies: Observations and Insights , 2011, Clinical pharmacology and therapeutics.
[4] P. Honig. Comparative Effectiveness: The Fourth Hurdle in Drug Development and a Role for Clinical Pharmacology , 2011, Clinical pharmacology and therapeutics.
[5] J. Kramer,et al. Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values. , 2009, The New England journal of medicine.
[6] J. Werth,et al. The Use of a Clinical Utility Index to Compare Insomnia Compounds: A Quantitative Basis for Benefit–Risk Assessment , 2009, Clinical pharmacology and therapeutics.
[7] R. Tamura,et al. Global benefit–risk assessment in designing clinical trials and some statistical considerations of the method , 2008, Pharmaceutical statistics.
[8] Christy Chuang-Stein,et al. Measures for Conducting Comparative Benefit: Risk Assessment , 2008 .
[9] Robert T. O'Neill,et al. A Perspective on Characterizing Benefits and Risks Derived from Clinical Trials: Can We Do More? , 2008 .
[10] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[11] R. Temple. Quantitative Decision Analysis: A Work in Progress , 2007, Clinical pharmacology and therapeutics.
[12] M Pirmohamed,et al. Current Assessment of Risk–Benefit by Regulators: Is It Time to Introduce Decision Analyses? , 2007, Clinical pharmacology and therapeutics.
[13] Sam Salek,et al. Retracted:A quantitative approach to benefit‐risk assessment of medicines — part 2: the practical application of a new model , 2007, Pharmacoepidemiology and drug safety.
[14] Sam Salek,et al. A quantitative approach to benefit‐risk assessment of medicines – part 1: the development of a new model using multi‐criteria decision analysis , 2007, Pharmacoepidemiology and drug safety.
[15] H. Mouridsen,et al. Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] R. Entsuah,et al. Global Benefit-risk Evaluation of Antidepressant Action: Comparison of Pooled Data for Venlafaxine, SSRIs, and Placebo , 2002, CNS Spectrums.
[17] Richard Entsuah,et al. Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. , 2002, Journal of psychiatric research.
[18] C Chuang-Stein,et al. A new proposal for benefit-less-risk analysis in clinical trials. , 1994, Controlled clinical trials.
[19] C Chuang-Stein,et al. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. , 1991, Statistics in medicine.
[20] R. Gelber,et al. Quality adjusted survival analysis. , 1990, Statistics in medicine.
[21] R. Gelber,et al. A quality-of-life-oriented endpoint for comparing therapies. , 1989, Biometrics.